- Akari Therapeutics ( NASDAQ: AKTX ) announce d positive results from recent pre-clinical studies on the tolerability and extended dose interval of long-acting PAS-nomacopan in development for geographic atrophy (GA) in dry age-related macular degeneration.
- GA is a chronic progressive degeneration of the macula, which occurs during late-stage dAMD and can lead to irreversible vision loss.
- The result showed that the half-life within the eye of intravitreally injected early generation PAS-nomacopan (also referred to as PAS600 nomacopan) in a standard ophthalmic pre-clinical model can be accurately predicted, the company said.
For further details see:
Akari Therapeutics announces positive results from pre-clinical studies of eye disease treatment